Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.
Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
5funds adding
6new positions
$8.80Bheld by those funds
AIThis scan
Comparing the Q2 2026 13F window (period 2026-06-30, filed August) against Q1 2026 (period 2026-03-31) across Berkshire Hathaway, Bridgewater, Renaissance Technologies, Citadel Advisors, and Two Sigma, 787 manager-tickers survived the aggregate-acceleration gate (net buyers > sellers AND either ≥25% aggregate Q/Q share growth or ≥2 funds opening new positions). After filtering for mega-cap retail favorites, sector ETFs, liquidity rails, earnings-event risk within seven trading days, and — most importantly — retail attention that is NOT yet elevated, five names surface. The single most surprising finding: Buffett is still scaling up Delta Air Lines (+44% Q/Q to 57.3M shares, now a $5.4B position), six years after his famous March-2020 airline exit. That is Berkshire's single biggest proportional add among its existing large positions this quarter, and the price went with him — DAL is up ~41% quarter-on-quarter, meaning Buffett is buying into strength, which is atypical. The rest of the list (ICE, MCK, MDT, SHEL) is a quieter picture: boring cash-generative franchises where the quants and Bridgewater are opening or scaling positions in lockstep while retail attention and short-dated options positioning remain muted.
How this scan was run
Signal is Q2 2026 (reportDate 2026-06-30) vs Q1 2026 (reportDate 2026-03-31) 13F-HR filings pulled from EDGAR via fetch_13f_holdings. For each CUSIP, shares were summed across each fund's sub-accounts, PUT-option holdings excluded, and per-fund Q/Q deltas computed. A CUSIP qualifies when net-buyer count exceeds net-seller count AND either aggregate shares grew ≥25% Q/Q or ≥2 funds opened a brand-new position. Single-fund concentration >80% of the aggregate increase disqualifies unless Berkshire is the buyer (Buffett block buys are the signal). All five funds returned both quarters' filings; none failed. Renaissance, Citadel, and Two Sigma are weighted DOWN in thesis-writing because their intra-quarter turnover is high and 13F is a lagged, partial snapshot. Berkshire and Bridgewater carry more weight. CUSIP→ticker resolved via issuer name and verified through live Tradier quotes; no dual-class ambiguities among the final five (Alphabet Class A/C were deprioritized as a retail-favorite mega-cap). 13F lags 45 days; the Q2 filings were submitted mid-August, so the funds' views are already four to five months stale as of publication. Average-entry price estimates are value-at-quarter-end ÷ shares and are NOT cost basis — they're approximately where positions were marked on June 30.
#1
DAL
Delta Air Lines Inc.
IndustrialsMkt cap $56.4BNext earnings Jan 13, 2027
Price
$87.20
Est. fund entry
$93.66-6.9%
Shares held
57.4M
Position value
$5.37B
Funds that added
Fund
Prior shares
Shares now
Change
Berkshire Hathaway
39.8M
57.3M
+44.0%
Two Sigma Investments
—
22.2K
New position
Bridgewater Associates
22.1K
22.4K
+1.1%
Retail attention 3 of 4 signals quiet
Google Trends22/100quiet
News, 30 days18 articlesbusy
Call/put OI1.30quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Berkshire added 17.5M shares of Delta in Q2 at an average quarter-end mark of ~$93.70 — a 44% add to what was already a $2.6B position, and the single biggest proportional scale-up of an existing Berkshire holding this filing. That matters specifically because Buffett dumped every airline in March 2020 at the pandemic lows and publicly called the decision correct; returning this aggressively, and buying into a 41% quarterly rally, breaks the pattern. Delta's edge over peers has tightened — premium-cabin and co-brand credit-card revenue now covers roughly half of operating profit, insulating earnings from the leisure-fare softening that is hitting ULCCs. The catalyst retail hasn't priced: if Buffett is still here at Q3 filings, it de-risks DAL to a wider pool of generalist funds that still refuse to touch airlines on principle.
What would prove it wrong
DAL is up 41% QoQ already — Berkshire's own average entry in the latest tranche is above today's print, so cheaper lots exist. A fuel spike, a credit-card promotional giveback, or an industry capacity reacceleration into 2027 would compress the premium-cabin margin story quickly. Berkshire can also exit as fast as it entered.
#2
ICE
Intercontinental Exchange Inc.
FinancialsMkt cap $98.4BNext earnings Feb 5, 2027
Price
$172.27
Est. fund entry
$123.12+39.9%
Shares held
6.56M
Position value
$807.8M
Funds that added
Fund
Prior shares
Shares now
Change
Renaissance Technologies
—
1.27M
New position
Citadel Advisors
1.86M
3.22M
+73.3%
Two Sigma Investments
—
2.03M
New position
Bridgewater Associates
—
38.9K
New position
Retail attention 4 of 4 signals quiet
Google Trends11/100quiet
News, 30 days9 articlesquiet
Call/put OI1.10quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Three of four supporting funds — RenTech, Two Sigma, Bridgewater — opened NEW positions in ICE in Q2, and Citadel scaled theirs by 73%. Four of five configured funds moving the same direction, with three of them going from zero, is the rarest pattern this scan produces. The common read: ICE's mortgage-tech stack (post-Black Knight) is finally monetizing into a re-fi cycle while the exchange and fixed-income data businesses keep compounding at mid-teens. The catalyst retail hasn't priced: if US 30-year mortgage rates break the 6% psychological level into Q1 2027, ICE's Encompass origination volumes inflect — and it's one of the only public pure-plays on that funnel. The quant funds don't usually open simultaneously on a thesis; they're pattern-matching something.
What would prove it wrong
Bridgewater's position is a token $4.8M — macro-fund breadcrumb, not conviction. If mortgage rates stay sticky above 6.5%, the Black Knight integration thesis stalls and the stock trades like a pure exchange comp (CME, CBOE) without the growth premium.
#3
MCK
McKesson Corporation
Health CareMkt cap $136.9BNext earnings Feb 4, 2027
Price
$1,060.84
Est. fund entry
$755.52+40.4%
Shares held
1.04M
Position value
$787.8M
Funds that added
Fund
Prior shares
Shares now
Change
Renaissance Technologies
117.2K
361.1K
+208.0%
Citadel Advisors
189.7K
601.8K
+217.2%
Two Sigma Investments
6.20K
9.45K
+52.4%
Bridgewater Associates
67.4K
70.4K
+4.4%
Retail attention 4 of 4 signals quiet
Google Trends14/100quiet
News, 30 days12 articlesquiet
Call/put OI0.90quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
RenTech tripled its stake and Citadel more than tripled theirs — on a $136B-cap boring pharma distributor that trades at 17x earnings. Four-fund breadth with zero sellers is the cleanest accumulation pattern in this scan. The GLP-1 dispensing wave is the setup: McKesson's specialty pharmacy arm (CoverMyMeds + RxCrossroads) is the top prior-auth and bioreactive-handling route for Zepbound and Wegovy at retail scale, and the business line is growing in the mid-20s % versus the legacy 4% distribution book. The catalyst retail hasn't priced: GLP-1 oral formulations (Lilly's orforglipron) enter the US channel in 2027 and distribution-weighted volumes jump an order of magnitude versus injectables. MCK has the only built-out cold-chain substitute network to handle the pivot.
What would prove it wrong
Fiscal Q2 was reported Nov 4 — if the just-released quarter disappointed on specialty margin, the 13F thesis is already contradicted by newer public data. DEA re-tightening of controlled-substance distribution quotas remains a tail risk that has hit MCK before.
#4
MDT
Medtronic PLC
Health CareMkt cap $130.3BNext earnings Nov 24, 2026
Price
$101.80
Est. fund entry
$78.22+30.1%
Shares held
13.1M
Position value
$1.02B
Funds that added
Fund
Prior shares
Shares now
Change
Renaissance Technologies
—
3.17M
New position
Citadel Advisors
2.45M
6.20M
+153.1%
Two Sigma Investments
626.9K
3.24M
+417.0%
Bridgewater Associates
255.2K
482.5K
+89.0%
Retail attention 3 of 4 signals quiet
Google Trends17/100quiet
News, 30 days21 articlesbusy
Call/put OI1.20quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Four-fund accumulation with aggregate shares nearly quadrupling Q/Q. Citadel went from 2.5M to 6.2M shares, Two Sigma from 630k to 3.2M (+417%), and Bridgewater — a macro fund that rarely touches medtech — nearly doubled. The set-up: Medtronic is spinning its Diabetes business in Q1 2027, which the sell-side has been modeling at a $10–12B standalone valuation. Pure-play RemainCo would carry a higher multiple than today's conglomerate discount — the sum-of-the-parts case is six to eight points of P/E re-rating. The catalyst retail hasn't priced: the spin prospectus lands in December-January, and historically multi-day-move medtech spin filings have been the kind of event that quant shops pre-position for.
What would prove it wrong
MDT reports fiscal Q2 on Nov 24 — only ~11 trading days out, inside the normal earnings event window if entering now. A guide-down on PFA ablation-catheter volumes (the Affera-powered platform) would compress the spin thesis. Also, the Bridgewater adds across the board in Q2 may reflect a generic defensive rotation trade, not name-specific conviction.
#5
SHEL
Shell PLC (ADR)
EnergyMkt cap $298.0BNext earnings Feb 4, 2027
Price
$99.09
Est. fund entry
$77.56+27.8%
Shares held
10.4M
Position value
$809.8M
Funds that added
Fund
Prior shares
Shares now
Change
Renaissance Technologies
—
2.70M
New position
Citadel Advisors
4.89M
5.62M
+14.9%
Two Sigma Investments
301.7K
598.5K
+98.4%
Bridgewater Associates
312.2K
1.53M
+388.9%
Retail attention 3 of 4 signals quiet
Google Trends23/100quiet
News, 30 days28 articlesbusy
Call/put OI1.00quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Bridgewater took their SHEL position nearly 5x (+389%) and RenTech opened new — Bridgewater almost never 5x's an existing position quarter-to-quarter, which makes this the most macro-signaling line in the scan. The read: slower-moving macro desks are leaning into integrated energy as a hedge against a persistent oil-price floor (OPEC+ discipline into 2027) AND against a weaker USD scenario where non-US-listed majors re-rate in dollar terms. Shell specifically has the industry's lowest net-debt-to-equity post-$5B buyback acceleration, and its LNG portfolio prints cash whether Europe stays warm or cold. The catalyst retail hasn't priced: if the EU reinstates a Russian-gas backstop ban into 2027 (currently under Council review), Shell's LNG optionality on existing Gorgon/Prelude flows gets repriced upward.
What would prove it wrong
Energy was broadly bought by macro funds in Q2 as a reflation trade; this could be a sector-basket add, not Shell-specific conviction. If OPEC+ cohesion breaks, Shell trades with the group regardless of refining differentials. Bridgewater can also exit sector trades in a single filing.
Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds
and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones —
while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a
new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.